Harnessing more than twelve years’ experience in the scaled manufacturing of neural stem cells, we are developing proprietary exosomes for the treatment of CNS injury and neurodegenerative disorders, with an initial focus in stroke.

Exosomes have shown great promise as potential therapeutics and as vehicles to carry drug payloads to the site of injury or disease. They:

  • Are micro-sized biologics produced by stem cells

  • Act as cell-to-cell messengers

  • Contain bio-molecular cargo of RNA, DNA, miRNA, and Proteins

  • Bleb or bubble off cells during growth and differentiation and serve as master regulators for cellular signaling

  • Have the potential to target any cell in the body

  • Are capable of crossing the blood brain barrier (BBB)

  • Can carry cargo such as drugs to cells

  • Have the potential to “home” to a site of injury or disease and initiate repair

Our lead candidate, AB126, has demonstrated to reduce inflammation and inflammatory signals, and provided functional improvement in preclinical studies.

The neural stem cell-derived exosomes we harvest from our proprietary manufacturing process have demonstrated the ability to:

  • Reduce inflammation and enhance neural function
  • Cross the blood brain barrier non-invasively to reach the site of injury
  • Enable multiple intravenous (IV) dosing without adverse response

To learn more about our exosomes, click here.